1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,170 | 3,290 | 22.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.07. | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | 336 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 412 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 30.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 328 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
30.06.2026 / 13:08 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.06. | EMA committee issues negative opinion on MaaT Pharma's MaaT013 | 4 | Investing.com | ||
| 26.06. | MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease | 1.048 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013... ► Artikel lesen | |
| 11.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 305 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
11.06.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 | 924 | Business Wire | MaaT013 (Xervyteg):
In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use... ► Artikel lesen | |
| 20.05. | MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease | 895 | Business Wire | During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a "negative trend" opinion for the upcoming June... ► Artikel lesen | |
| 11.05. | MaaT Pharma to Hold Annual General Meeting on June 16, 2026 | 394 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 21.04. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy | 358 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
21.04.2026 / 15:09 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 01.04. | MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal | 540 | Business Wire | CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy
Results... ► Artikel lesen | |
| 31.03. | MaaT Pharma Announces 2025 Annual Results and Provides Business Updates | 623 | Business Wire | Potential Pivotal Year for MaaT013 (Xervyteg):
Marketing Authorization Application (MAA) in Europe for MaaT013 (Xervyteg) submitted to the European Medicines Agency (EMA) in June 2025
... ► Artikel lesen | |
| 23.03. | MaaT Pharma presents phase 3 trial results for aGvHD treatment | 2 | Investing.com | ||
| 23.03. | MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation | 444 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 09.03. | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | 706 | Business Wire | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| 03.02. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 453 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 20.01. | MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis | 726 | Business Wire | IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease... ► Artikel lesen | |
| 10.12.25 | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 528 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 08.12.25 | MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival | 843 | Business Wire | Presentation included previously disclosed primary results from the pivotal ARES Phase 3 single-arm trial evaluating MaaT013 (Xervyteg) in treating refractory severe acute Graft-versus-Host Disease... ► Artikel lesen | |
| 19.11.25 | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 480 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
19.11.2025 / 11:11 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 59,70 | +0,34 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| BRAIN BIOTECH | 2,700 | -0,37 % | Brain Biotech: Sven K. Weber wird neuer Vorstandsvorsitzender | Der Aufsichtsrat der Brain Biotech AG hat Sven K. Weber zum 1. Oktober 2026 für drei Jahre zum neuen Vorstandsvorsitzenden bestellt. Der 44-Jährige war seit 2011 in verschiedenen Führungspositionen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,020 | +0,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| KUROS BIOSCIENCES | 23,020 | -0,26 % | Strategie und Potenzial: Kuros Biosciences setzt auf langfristiges Wachstum | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | -5,09 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,280 | 0,00 % | H.C. Wainwright reiterates Microbot Medical stock rating on revenue growth | ||
| ATAIBECKLEY | 6,400 | +0,79 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DXCM, ORKA, CON, ATAI | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| IMMATICS | 7,565 | -1,18 % | Immatics Announces Second Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,060 | -0,70 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| BEONE MEDICINES LTD ADR | 326,00 | +1,24 % | HSI Up 291 pts; HSTI Up 72 pts; XIAOMI Up over 3%; WUXI BIO, WUXI APPTEC, BEIGENE, OOIL, TINGYI Hit New Highs | ||
| BIOMERIEUX | 74,80 | -0,07 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| CYBIN | 10,980 | +1,67 % | Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board | Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,712 | +3,19 % | BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August | ||
| BIO GREEN MED SOLUTION | 0,871 | +0,68 % | Bio Green Med Solution, Inc. - S-4/A, Registration of securities, business combinations | ||
| PDS BIOTECHNOLOGY | 0,194 | +4,03 % | PDS Biotechnology: CFO tritt zurück, Interimsnachfolge geregelt |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,16 % bei einem Aktienkurs von 3,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.